Progesterone receptor testing: Not the right time to be buried [15]

Journal of Clinical Oncology

Volumn 23, Issue 16, 2005, Pages 3867-3868

  Colozza, M ^a   Larsimont, D ^a   Piccart, M J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; LETTER; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; TUMOR RECURRENCE; BREAST TUMOR; CANCER STAGING; DECISION MAKING; FEMALE; METABOLISM; NOTE; PATHOLOGY; PATIENT CARE PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; NEOPLASM STAGING; PATIENT CARE PLANNING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 20544439852     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.167     Document Type: Letter

References (12)

1. Olivotto IA, Truong PT, Speers C, et al: Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 22:1769-1770, 2004
2. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study, Int J Cancer 89:111-117, 2000
3. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
4. Bardou V-J, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003
5. Femo M, Stal O, Baldertop B, et al: Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels: South Sweden Breast Cancer Group and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59:69-76, 2000
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
7. Rutqvist LE, Cedermark B, Pomander T, et al: The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 7:1474-1484, 1989
8. Dowsett M on behalf of the ATAC Trialists Group: Analysis of time to r0ecurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 83:S7, 2003 (suppl 1; abstr 4)
9. Kastner P, Krust A, Turcotte B, et al: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptors forms A and B. EMBO J 9:1603-1614, 1990
10. Kraus WL, Katzenellenbogen BS: Regulation of progesterone receptor gene expression and growth in the rat uterus: Modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology 132:2371-2379, 1993
11. Richer JK, Jacobsen BM, Manning NG, et al: Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209-5218, 2002
12. Hoop TA, Weiss HI, Hilsenbeck SG, et al: Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10:2751-2760, 2004